Skip to main content

Table 2 Patient characteristics and 3-month survival

From: A prospective randomized open-label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis by the Molecular Adsorbents Recirculating System

Patient Age Etiology Child MELD Day 1 Sessions 3m survival
1 52 Alcoholic B9 22 citrate 4 deceased
2 47 Alcoholic C13 43 nil 3 deceased
3 32 Alcoholic C11 26 nil 3 transplanted, alive
4 68 Hepatitis C C11 34 citrate 2 lost to follow up
5 51 Alcoholic C10 23 nil 3 alive
6 63 Alcoholic C10 30 citrate 4 alive
7 65 Graft failure B9 23 citrate 3 alive
8 50 NASH C12 36 nil 3 transplanted, alive
9 64 Alcoholic C13 34 nil 1 deceased
10 54 α1-AT deficiency C13 50 citrate 1 deceased
  1. α1-AT deficiency, α1-antitrypsin deficiency; MELD, model for end-stage liver disease